Rare disease focus Modis Therapeutics is a small biotech focused on disease-modifying therapies for rare genetic diseases, presenting an opportunity to position partnerships or advisory services around orphan drug development, regulatory strategy, and patient access programs.

Acquisition by Zogenix As a wholly owned subsidiary of Zogenix, Modis may benefit from corporate synergies, access to larger capital and distribution networks; sales outreach could explore expanded collaboration, licensing, or co-development opportunities within the Zogenix ecosystem.

Lead program TK2d MT1621 for thymidine kinase 2 deficiency targets a high-need mitochondrial disease, suggesting sales angles in specialty pharma channels, research collaborations, and clinical trial support services for rare metabolic disorders.

Early-stage funding With modest annual revenue and substantial funding (under 1M revenue but $30M raised), there is potential for services around grant consulting, clinical development outsourcing, and strategic partnerships to accelerate key programs.

Global exposure Being part of a global pharmaceutical family and leveraging tools like NetSuite and QuickBooks indicates established operations; opportunities exist for enterprise software, CRO partnerships, and financial systems integration services to support scale.